Bianucci P, Pastorino G, De Rossi O
Minerva Med. 1979 May 26;70(25):1795-801.
The personal series consists of 140 cancer patients followed up over a period of some 3 years and submitted prior to the start of treatment to the DNCB skin test. This test indicates the patient's immune condition and the degree of reactivity shown may be useful prognostically for assessing the course of the disease and its response to immunochemotherapeutic treatment; this was confirmed in 77% of case. The skin test has now been personally associated with CEA radio-immunological metering for patients suffering from breast, lung and digestive system cancer (40 cases in all). The hypothesis, which is supported by the results obtained, is that there is a correlation between CEA titre and skin reactivity to the immunostimulus; in effect, high CEA titres have generally always corresponded to little or no DNCB skin reactivity and vice versa.
个人病例系列包括140名癌症患者，随访约3年，并在治疗开始前进行了二硝基氯苯（DNCB）皮肤试验。该试验可表明患者的免疫状况，所显示的反应程度在预后评估疾病进程及其对免疫化疗治疗的反应时可能有用；在77%的病例中得到了证实。目前，对于患有乳腺癌、肺癌和消化系统癌症的患者（共40例），已将皮肤试验与癌胚抗原（CEA）放射免疫测定亲自关联起来。所得结果支持的假设是，CEA滴度与皮肤对免疫刺激的反应性之间存在相关性；实际上，高CEA滴度通常总是对应着很少或没有DNCB皮肤反应性，反之亦然。
